ICAM-1 expression in cytokine-treated full-length and mutant PECAM-1–transfected REN cells
| Cell line . | RHP . | PITC . | PECAM-ΔCD . | AAAA . |
|---|---|---|---|---|
| Vehicle | 17.9 (3.34) | 24.0 (5.36) | 2.19 (0.17)* | 23.8 (3.78) |
| IL-1β | 39.7 (11.6) | 35.5 (7.50) | 3.67 (0.93)* | 37.6 (9.10) |
| Fold increase | 2.15 (0.43) | 1.49 (0.17) | 1.66 (0.38) | 1.56 (0.28) |
| Cell line . | RHP . | PITC . | PECAM-ΔCD . | AAAA . |
|---|---|---|---|---|
| Vehicle | 17.9 (3.34) | 24.0 (5.36) | 2.19 (0.17)* | 23.8 (3.78) |
| IL-1β | 39.7 (11.6) | 35.5 (7.50) | 3.67 (0.93)* | 37.6 (9.10) |
| Fold increase | 2.15 (0.43) | 1.49 (0.17) | 1.66 (0.38) | 1.56 (0.28) |
ICAM-1 surface expression in confluent PECAM-1 transfectant cell monolayers treated for 24 hours with IL-1β or vehicle. FACS analysis was conducted on nontrypsinized cells with primary anti–ICAM-1 mAb LR6.5. Mean fluorescence intensity values (± SEM) were obtained from 3 separate experiments. Fold increase (± SEM) is the mean fold increase above untreated ICAM-1 expression (n = 3). There was no significant difference between fold increase values.
PECAM-ΔCD ICAM-1 expression is significantly lower than other cell lines (P < .05).